July 11 2024
Dr. Mei-Yin Polley has been promoted to Full Professor in the Department of Public Health Sciences at the University of Chicago. Dr. Polley joined NRG Oncology Statistics and Data Management Center (SDMC) in 2020 and has since held positions as the Head of Statistics Division of SDMC and the Lead Statistician for the Brain Tumor Committee for NRG Oncology. During her time with NRG, her collaborative research endeavor has focused on overseeing the statistical activities of the Brain Tumor Committee. Notably, she has been instrumental in gaining the approval or activation status of multiple brain tumor trials and completing several important collaborative manuscripts as the primary statistician. Previously, Dr. Polley held positions as an Assistant Professor in the Department of Neurosurgery at UCSF, a mathematical statistician in the Biometric Research Program at the National Cancer Institute (NCI), and an Associate Professor of Biostatistics in the Department of Quantitative Health Sciences at Mayo Clinic.
Dr. Polley has 17 years of experience as a cancer clinical trial biostatistician. Her statistical methods research has spanned a variety of areas including early-phase clinical trial designs, biomarker reproducibility, group sequential methods for biomarker validation, and design and analysis of biomarker-based clinical trials. Her expertise has led to invitations to influential positions as a statistical advisor including the Federal Advisory Committee of the US Department of Veterans Affairs (VA), the Scientific Committee of American Society of Clinical Oncology (ASCO), and the Scientific Committee of the CNS Clinical Trials conference, among many others. She has been competitively elected to numerous national scientific governing or advisory bodies including the NCI’s National Clinical Trials Network (NCTN) Steering Committees for trials in lymphoma and head and neck cancer. Dr. Polley’s support to the NRG SDMC will continue to focus on promoting rigorous clinical trial methodology to be employed in NRG Oncology trials.